Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Hyman

Showing results (131-140 of 174) with videos related to

Pageof 18
Sort By:
NPJ Breast Cancer|April 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancerLillian M Smyth, Gerald Batist, Funda Meric-Bernstam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2020
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> <sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast CancerLillian M Smyth, Kenji Tamura, Mafalda Oliveira, et al.
Nature Medicine|August 14, 2019
Resistance to TRK inhibition mediated by convergent MAPK pathway activationEmiliano Cocco, Alison M Schram, Amanda Kulick, et al.
Cancer Cell|January 10, 2018
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal CancerRona Yaeger, Walid K Chatila, Marla D Lipsyc, et al.
JAMA Oncology|July 22, 2016
The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing PlatformLuc G T Morris, Raghu Chandramohan, Lyndsay West, et al.
Cancer Treatment Reviews|May 21, 2019
Improving attribution of adverse events in oncology clinical trialsGoldy C George, Pedro C Barata, Alicyn Campbell, et al.
Science Signaling|October 11, 2018
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)Emiliano Cocco, F Javier Carmona, Pedram Razavi, et al.
The Lancet. Oncology|February 28, 2020
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsDavid S Hong, Steven G DuBois, Shivaani Kummar, et al.
JAMA Oncology|July 7, 2018
Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell CarcinomaMaria I Carlo, Semanti Mukherjee, Diana Mandelker, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Pageof 18

Showing results (131-140 of 174) with videos related to

Sort By:
Pageof 18
NPJ Breast Cancer|April 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancerLillian M Smyth, Gerald Batist, Funda Meric-Bernstam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2020
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> <sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast CancerLillian M Smyth, Kenji Tamura, Mafalda Oliveira, et al.
Nature Medicine|August 14, 2019
Resistance to TRK inhibition mediated by convergent MAPK pathway activationEmiliano Cocco, Alison M Schram, Amanda Kulick, et al.
Cancer Cell|January 10, 2018
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal CancerRona Yaeger, Walid K Chatila, Marla D Lipsyc, et al.
JAMA Oncology|July 22, 2016
The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing PlatformLuc G T Morris, Raghu Chandramohan, Lyndsay West, et al.
Cancer Treatment Reviews|May 21, 2019
Improving attribution of adverse events in oncology clinical trialsGoldy C George, Pedro C Barata, Alicyn Campbell, et al.
Science Signaling|October 11, 2018
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)Emiliano Cocco, F Javier Carmona, Pedram Razavi, et al.
The Lancet. Oncology|February 28, 2020
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsDavid S Hong, Steven G DuBois, Shivaani Kummar, et al.
JAMA Oncology|July 7, 2018
Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell CarcinomaMaria I Carlo, Semanti Mukherjee, Diana Mandelker, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Pageof 18